Category - Developments

Developments

Blume raises seed capital for young women’s self help and period products

Closely-held Blume, a young women’s self help and periods products company, raised $3.3-million in a seed funding round, led by Grace Chou and Victoria Treyger, partners at Felicis Ventures, with participation from...

April 1, 2019

Developments

CHMP affirms omega-3s do not prevent further problems after heart attack

The European Medicine Agency’s (EMA) advisory committee (CHMP) affirmed that a 1gm daily dose of omega-3s are not effective in preventing further cardiovascular (CV) problems in patients who have had a heart attack. The...

March 29, 2019

Developments

Supernus Pharma again posts positive Phase 3 ADHD data

Supernus Pharma (NASDAQ:SUPN) announced top-line results from P304, its Phase 3 study of SPN-812 in adolescents with attention deficit hyperactivity disorder (ADHD). SPN-812 is a non-stimulant serotonin norepinephrine...

March 29, 2019

Developments

Fluidigm introduces new immune profiling system

Fluidigm’s (NASDAQ:FLDM) new immune profiling system, Maxpar Direct, quantifies immune cell populations with automated five-minute results reporting. Maxpar Direct uses a single-tube workflow to profile 37 different...

March 28, 2019

Developments

Neuronetics receives Japanese reimbursement for NeuroStar’s TMS Therapy

Transcranial magnetic stimulation (TMS) pioneer, Neuronetics (NASDQ:STIM), received reimbursement approval from Japan’s Central Social Insurance Medical Council for its NeuroStar Advanced Therapy for the treatment...

March 28, 2019

Developments

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a...

March 28, 2019

Developments

Lutronic Vision retains retina expert to lead R:GEN pilot AMD clinical study

Closely-held Lutronic Vision retained professor Robyn Guymer, a world-renowned age-related macular degeneration (AMD) expert and key opinion leader, to serve as the principal investigator for its planned pilot clinical...

March 27, 2019

Developments

BeyondSpring to present promising new strategy for cancer treatment with Plinabulin

BeyondSpring (NASDAQ: BYSI) will present a promising new strategy for cancer treatment involving the ability of its lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for a beneficial anti...

March 26, 2019

Developments

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

BeyondSpring (NASDAQ: BYSI) will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) annual meeting in...

March 25, 2019

Developments

Gritstone doses first patient in personalized immunotherapy trial

Gritstone Oncology (NASDAQ:GRTS) dosed the first patient with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001. The Phase 1/2 clinical study is evaluating...

March 22, 2019

Category - Developments

Blume raises seed capital for young women’s self help and period products

CHMP affirms omega-3s do not prevent further problems after heart attack

Supernus Pharma again posts positive Phase 3 ADHD data

Fluidigm introduces new immune profiling system

Neuronetics receives Japanese reimbursement for NeuroStar’s TMS Therapy

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Lutronic Vision retains retina expert to lead R:GEN pilot AMD clinical study

BeyondSpring to present promising new strategy for cancer treatment with Plinabulin

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

Gritstone doses first patient in personalized immunotherapy trial

General

More